食管鳞状细胞癌的个性化靶向治疗：最新进展
Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.
作者信息
Liu Yongjing, Xiong Zhaohui, Beasley Andrea, D'Amico Thomas, Chen Xiaoxin Luke
机构信息
Department of Cardiothoracic Surgery, 105th Hospital of PLA, Hefei, Anhui Province, China.
Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina.
出版信息
Ann N Y Acad Sci. 2016 Oct;1381(1):66-73. doi: 10.1111/nyas.13144. Epub 2016 Jul 11.
Abstract
Esophageal squamous cell carcinoma (ESCC) is a deadly disease that requires extensive research. In this review, we update recent progress in the research area of targeted therapy for ESCC. SOX2 and its associated proteins (e.g., ΔNP63α), which regulate lineage survival of ESCC cells, are proposed as therapeutic targets. It is believed that targeting the lineage-survival mechanism may be more effective than targeting other mechanisms. With the advent of a new era of personalized targeted therapy, there is a need to move from the tumor-centric model into an organismic model.
摘要
食管鳞状细胞癌（ESCC）是一种需要深入研究的致命疾病。在本综述中，我们更新了ESCC靶向治疗研究领域的最新进展。SOX2及其相关蛋白（如ΔNP63α）可调节ESCC细胞的谱系存活，被提议作为治疗靶点。人们认为，针对谱系存活机制进行靶向治疗可能比针对其他机制更有效。随着个性化靶向治疗新时代的到来，有必要从以肿瘤为中心的模式转向整体模式。
相似文献
1
Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.食管鳞状细胞癌的个性化靶向治疗：最新进展
Ann N Y Acad Sci. 2016 Oct;1381(1):66-73. doi: 10.1111/nyas.13144. Epub 2016 Jul 11.
2
Comprehensive Exploration to Identify Predictive DNA Markers of ΔNp63/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma.全面探索鉴定人食管鳞癌中 ΔNp63/SOX2 耐药的预测性 DNA 标志物。
Ann Surg Oncol. 2019 Dec;26(13):4814-4825. doi: 10.1245/s10434-019-07795-w. Epub 2019 Sep 16.
3
MicroRNAs in esophageal squamous cell carcinoma: Potential biomarkers and therapeutic targets.食管鳞状细胞癌中的微小RNA：潜在的生物标志物和治疗靶点。
Cancer Biomark. 2017;19(1):1-9. doi: 10.3233/CBM-160240.
4
Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.食管鳞状细胞癌的基因组特征：来自下一代测序的见解
World J Gastroenterol. 2016 Feb 21;22(7):2284-93. doi: 10.3748/wjg.v22.i7.2284.
5
SOX2 Promotes the Epithelial to Mesenchymal Transition of Esophageal Squamous Cells by Modulating Slug Expression through the Activation of STAT3/HIF-α Signaling.SOX2通过激活STAT3/HIF-α信号通路调节Slug表达，促进食管鳞状细胞上皮-间质转化。
Int J Mol Sci. 2015 Sep 8;16(9):21643-57. doi: 10.3390/ijms160921643.
6
Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.食管鳞状细胞癌（ESCC）的基因组分析——精准医学的基础
Pathol Res Pract. 2017 Jul;213(7):836-841. doi: 10.1016/j.prp.2017.02.021. Epub 2017 Feb 28.
7
Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma.食管基底样鳞状细胞癌的分子病理学及潜在治疗靶点
Int J Clin Exp Pathol. 2015 Mar 1;8(3):2267-73. eCollection 2015.
8
Personalized targeted therapy for esophageal squamous cell carcinoma.食管鳞状细胞癌的个性化靶向治疗
World J Gastroenterol. 2015 Jul 7;21(25):7648-58. doi: 10.3748/wjg.v21.i25.7648.
9
Clinical potential of miR-3651 as a novel prognostic biomarker for esophageal squamous cell cancer.miR-3651作为食管鳞状细胞癌新型预后生物标志物的临床潜力
Biochem Biophys Res Commun. 2015 Sep 11;465(1):30-4. doi: 10.1016/j.bbrc.2015.07.109. Epub 2015 Jul 23.
10
Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma.Cripto-1作为癌症干细胞样细胞的功能标志物，可预测食管鳞状细胞癌患者的预后。
Mol Cancer. 2017 Apr 21;16(1):81. doi: 10.1186/s12943-017-0650-7.
引用本文的文献
1
Decursin Suppresses Esophageal Squamous Cell Carcinoma Progression via Orchestrated Cell Cycle Deceleration, Apoptotic Activation, and Oncoprotein Degradation.去甲二氢愈创木酸通过精心调控细胞周期减速、激活细胞凋亡和降解癌蛋白来抑制食管鳞状细胞癌进展。
Int J Mol Sci. 2025 Jun 4;26(11):5391. doi: 10.3390/ijms26115391.
2
Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects.食管癌药物递送的机遇：当前治疗方法和未来前景。
Mol Pharm. 2024 Jul 1;21(7):3103-3120. doi: 10.1021/acs.molpharmaceut.4c00246. Epub 2024 Jun 18.
3
Serum VEGF levels as a predictor of recurrence in patients with advanced‑stage esophageal squamous cell carcinoma following curative esophagectomy followed by chemotherapy or concurrent radiotherapy.血清血管内皮生长因子水平作为晚期食管鳞状细胞癌患者根治性食管切除术后化疗或同步放疗后复发的预测指标。
Mol Clin Oncol. 2023 Sep 15;19(5):86. doi: 10.3892/mco.2023.2682. eCollection 2023 Nov.
4
Exploring cell competition for the prevention and therapy of esophageal squamous cell carcinoma.探索细胞竞争在食管鳞癌预防和治疗中的作用。
Biochem Pharmacol. 2023 Aug;214:115639. doi: 10.1016/j.bcp.2023.115639. Epub 2023 Jun 7.
5
Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma.对 bulk 和单细胞基因表达谱进行综合分析，鉴定肿瘤相关巨噬细胞衍生的 CCL18 作为食管鳞状细胞癌的治疗靶点。
J Exp Clin Cancer Res. 2023 Feb 27;42(1):51. doi: 10.1186/s13046-023-02612-5.
6
Exosomes-derived miR-154-5p attenuates esophageal squamous cell carcinoma progression and angiogenesis by targeting kinesin family member 14.外泌体来源的 miR-154-5p 通过靶向驱动蛋白家族成员 14 抑制食管鳞癌细胞进展和血管生成。
Bioengineered. 2022 Feb;13(2):4610-4620. doi: 10.1080/21655979.2022.2037322.
7
Molecular mechanisms associated with chemoresistance in esophageal cancer.与食管癌化疗耐药相关的分子机制。
Cell Mol Life Sci. 2022 Feb 3;79(2):116. doi: 10.1007/s00018-022-04131-6.
8
Development of targeted therapy of NRF2 esophageal squamous cell carcinoma.NRF2 食管鳞癌的靶向治疗进展。
Cell Signal. 2021 Oct;86:110105. doi: 10.1016/j.cellsig.2021.110105. Epub 2021 Aug 4.
9
Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α-AKT-mTOR pathway in esophageal squamous cell carcinoma.阿帕替尼通过IRE-1α-AKT-mTOR途径诱导内质网应激介导的凋亡和自噬，并增强食管鳞状细胞癌对紫杉醇的细胞敏感性。
Cell Biosci. 2021 Jul 6;11(1):124. doi: 10.1186/s13578-021-00640-2.
10
EMT and Cancer Cell Stemness Associated With Chemotherapeutic Resistance in Esophageal Cancer.上皮-间质转化和癌细胞干性与食管癌化疗耐药性相关
Front Oncol. 2021 Jun 3;11:672222. doi: 10.3389/fonc.2021.672222. eCollection 2021.
本文引用的文献
1
TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.通过靶向测序鉴定食管癌中的TP53、PIK3CA、FBXW7和KRAS突变
Cancer Genomics Proteomics. 2016 May-Jun;13(3):231-8.
2
Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis.食管鳞状细胞癌的基因组特征揭示了肿瘤发生和预后不良背后的关键基因。
Am J Hum Genet. 2016 Apr 7;98(4):709-27. doi: 10.1016/j.ajhg.2016.02.021.
3
The tumor microenvironment in esophageal cancer.食管癌中的肿瘤微环境。
Oncogene. 2016 Oct 13;35(41):5337-5349. doi: 10.1038/onc.2016.34. Epub 2016 Feb 29.
4
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.日本人群食管鳞癌的基因组特征。
Gastroenterology. 2016 May;150(5):1171-1182. doi: 10.1053/j.gastro.2016.01.035. Epub 2016 Feb 10.
5
Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer.食管鳞状细胞癌和胃癌体细胞改变的基因组图谱
Cancer Res. 2016 Apr 1;76(7):1714-23. doi: 10.1158/0008-5472.CAN-15-0338. Epub 2016 Feb 8.
6
Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma.全基因组测序揭示食管鳞状细胞癌结构变异的多种模式。
Am J Hum Genet. 2016 Feb 4;98(2):256-74. doi: 10.1016/j.ajhg.2015.12.013. Epub 2016 Jan 28.
7
Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma.基因组分析显示，FAM84B和NOTCH信号通路与食管鳞状细胞癌的进展相关。
Gigascience. 2016 Jan 11;5:1. doi: 10.1186/s13742-015-0107-0. eCollection 2016.
8
Targeting transcription is no longer a quixotic quest.靶向转录不再是一个不切实际的追求。
Nat Chem Biol. 2015 Dec;11(12):891-4. doi: 10.1038/nchembio.1962.
9
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.在中国，NOTCH1和PIK3CA中的互斥突变与食管鳞状细胞癌的临床预后及化疗反应相关。
Oncotarget. 2016 Jan 19;7(3):3599-613. doi: 10.18632/oncotarget.6120.
10
Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.循环肿瘤细胞和循环肿瘤 DNA：临床应用之路上的挑战与机遇。
Clin Cancer Res. 2015 Nov 1;21(21):4786-800. doi: 10.1158/1078-0432.CCR-14-1190.
Zotero 插件